Phase 3 findings show the benefit of immunotherapy before surgery in those with macroscopic stage III node-positive melanoma.
Clinical Trials
In Stage III Melanoma, Immunotherapy Combo Before Surgery Leads to Improved Survival, Less Therapy
The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma.
Pembrolizumab/Vibostolimab Coformulation for Melanoma to be Discontinued
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.
Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma
The phase 3 KeyVibe-010 trial (NCT05665595) evaluating the combination of adjuvant vibostolimab (MK-7684A) and pembrolizumab (Keytruda) vs pembrolizumab alone in patients with resected high-risk stage IIB, IIC, III, and IV melanoma has been discontinued.